Corbus Pharmaceuticals (CRBP) to Release Earnings on Tuesday

Key Points

• Corbus Pharmaceuticals is expected to report its Q2 2025 earnings before the market opens on August 5th, with analysts predicting a loss of ($1.35) per share.
• The company's stock has experienced a remarkable 342% year-to-date surge, and currently trades at $9.59, well above its 12-month low of $4.64.
• Recent analyst ratings show a predominance of positive outlooks, with nine "buy" ratings and one "strong buy" rating, contributing to an average target price of $50.88.

Corbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report) is anticipated to post its Q2 2025 quarterly earnings results before the market opens on Tuesday, August 5th. Analysts expect Corbus Pharmaceuticals to post earnings of ($1.35) per share for the quarter.

Corbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.39) earnings per share for the quarter, missing the consensus estimate of ($1.26) by ($0.13). On average, analysts expect Corbus Pharmaceuticals to post $-4 EPS for the current fiscal year and $-6 EPS for the next fiscal year.

Corbus Pharmaceuticals Trading Up 0.4%

Shares of CRBP traded up $0.04 during mid-day trading on Friday, reaching $9.31. The company's stock had a trading volume of 122,153 shares, compared to its average volume of 122,735. Corbus Pharmaceuticals has a 1-year low of $4.64 and a 1-year high of $61.89. The stock has a market cap of $113.95 million, a P/E ratio of -2.21 and a beta of 3.20. The business has a 50-day simple moving average of $8.32 and a two-hundred day simple moving average of $7.85.

Institutional Investors Weigh In On Corbus Pharmaceuticals

An institutional investor recently bought a new position in Corbus Pharmaceuticals stock. AQR Capital Management LLC acquired a new stake in shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 107,983 shares of the biopharmaceutical company's stock, valued at approximately $573,000. AQR Capital Management LLC owned approximately 0.88% of Corbus Pharmaceuticals as of its most recent SEC filing. 64.64% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on CRBP. Royal Bank Of Canada lowered their target price on Corbus Pharmaceuticals from $65.00 to $58.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 7th. Oppenheimer lowered their target price on Corbus Pharmaceuticals from $60.00 to $56.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 7th. B. Riley assumed coverage on Corbus Pharmaceuticals in a research note on Wednesday. They set a "buy" rating and a $28.00 price objective on the stock. HC Wainwright lowered their price objective on Corbus Pharmaceuticals from $50.00 to $40.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. Finally, Lifesci Capital upgraded Corbus Pharmaceuticals to a "strong-buy" rating in a research note on Saturday, July 12th. One equities research analyst has rated the stock with a sell rating, nine have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $49.38.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.